Difference between revisions of "Semuloparin (AVE-5026)"
Jump to navigation
Jump to search
(Created page with "'''In clinical trials.''' ==General information== Class/mechanism: Hemisynthetic ultra low molecular weight heparin (ULMWH), binds to antithrombin III, accelerating its activ...") |
m (Text replacement - "http://www.ncbi.nlm" to "https://www.ncbi.nlm") |
||
| Line 2: | Line 2: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Hemisynthetic ultra low molecular weight heparin (ULMWH), binds to antithrombin III, accelerating its activity and inhibiting factor Xa, factor IIa, and thrombin.<ref>[https://www.sanofioncology.com/pipeline/semuloparin.aspx Semuloparin (AVE5026) manufacturer's website]</ref><ref name="SAVE-ONCO"> Agnelli G, George DJ, Kakkar AK, Fisher W, Lassen MR, Mismetti P, Mouret P, Chaudhari U, Lawson F, Turpie AG; SAVE-ONCO Investigators. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med. 2012 Feb 16;366(7):601-9. [http://www.nejm.org/doi/full/10.1056/NEJMoa1108898 link to original article] [ | + | Class/mechanism: Hemisynthetic ultra low molecular weight heparin (ULMWH), binds to antithrombin III, accelerating its activity and inhibiting factor Xa, factor IIa, and thrombin.<ref>[https://www.sanofioncology.com/pipeline/semuloparin.aspx Semuloparin (AVE5026) manufacturer's website]</ref><ref name="SAVE-ONCO"> Agnelli G, George DJ, Kakkar AK, Fisher W, Lassen MR, Mismetti P, Mouret P, Chaudhari U, Lawson F, Turpie AG; SAVE-ONCO Investigators. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med. 2012 Feb 16;366(7):601-9. [http://www.nejm.org/doi/full/10.1056/NEJMoa1108898 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/22335737 PubMed]</ref> |
Route: SC | Route: SC | ||
Revision as of 02:20, 2 December 2016
In clinical trials.
General information
Class/mechanism: Hemisynthetic ultra low molecular weight heparin (ULMWH), binds to antithrombin III, accelerating its activity and inhibiting factor Xa, factor IIa, and thrombin.[1][2]
Route: SC
Extravasation: n/a
Clinical trials
- Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Cancer Patients Undergoing Chemotherapy (SAVE-ONCO)[2]
- Evaluation of AVE5026 as Compared to Placebo for the Extended Prophylaxis of Venous Thromboembolism in Patients Having Undergone Hip Fracture Surgery (SAVE-HIP3)
- Study of AVE5026 at Weight-adjusted Doses in Children With a Central Venous Line
- Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Hip Fracture Surgery (SAVE-HIP2)
- Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Major Abdominal Surgery (SAVE-ABDO)
- Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Elective Knee Replacement Surgery (SAVE-KNEE)
- Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Total Hip Replacement Surgery (SAVE-HIP1)
- Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients With Restricted Mobility (SAVE-VEMED)
- Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement Surgery (TREK)
Patient drug information
No information available.
References
- ↑ Semuloparin (AVE5026) manufacturer's website
- ↑ 2.0 2.1 Agnelli G, George DJ, Kakkar AK, Fisher W, Lassen MR, Mismetti P, Mouret P, Chaudhari U, Lawson F, Turpie AG; SAVE-ONCO Investigators. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med. 2012 Feb 16;366(7):601-9. link to original article PubMed